Tests DAOIB for memory and thinking problems after COVID-19
Tests the drug DAOIB in adults with long COVID and cognitive problems.
Plain-language title generated from the registry record
Registry title: DAOIB for the Treatment of Brain Fog
Key facts
- Where
- Kaohsiung City, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05764538, who can take part
Where in Taiwan
- Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT05764538
- Record updated
- 23 October 2026
- Original description
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.Read full original descriptionShow less
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Inclusion: "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments; physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits; have sufficient education to communicate effectively and are capable of completing the assessments of the study.
Exclusion: history of significant cerebrovascular disease; major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments; Hachinski Ischemic Score > 4; memantine use (memantine is an NMDAR partial antagonist); substance (including alcohol) abuse or dependence; delusion, hallucination or delirium symptoms; severe visual or hearing loss; inability to follow the protocol.